同方股份终止与中国宝原中核医疗委托管理协议暨关联交易进展公告

同方股份有限公司关于终止《委托管理协议》暨关联交易进展公告深度解读

关键要点概述

同方股份有限公司（证券代码：600100）与其原控股股东中国宝原投资有限公司（以下简称“中国宝原”）签署了关于终止《委托管理协议》的相关协议。
本次终止协议涉及中国宝原全资子公司中核医疗产业管理有限公司（“中核医疗”）部分股东权利及经营管理权委托事项。
根据原协议，同方股份每年可获得40万元（含税）委托管理费用，托管期限为三年。
由于客观情况变化，双方决定终止该委托管理关系，并根据实际管理期限支付相应费用。

事件背景及详细说明

2024年7月26日，同方股份与中国宝原签署了《关于中核医疗产业管理有限公司委托管理协议》，约定中国宝原将其全资子公司中核医疗部分股东权利及经营管理权委托给同方股份行使，协议自生效日起三年，并约定每年支付40万元委托管理费用。该事项已于2024年7月27日对外公告。

然而，因客观环境发生变化，双方于近日签署了《委托管理协议之终止协议》，自终止协议生效之日起，正式终止原《委托管理协议》，并按照实际管理期限支付委托管理费用。

对公司的影响及投资者需关注的重要事项

公司明确表示，本次终止协议不会对公司正常经营活动产生不利影响。
不会对公司未来财务状况和经营成果产生重大不利影响。
不存在损害公司及股东，特别是中小股东利益的情形。
由于委托管理费用金额较小（每年40万元），终止协议整体对公司业绩影响有限，预计不会对公司股价产生重大波动。
此次关联交易的终止，表明公司与原控股股东之间的业务往来进一步清晰，有助于公司治理结构的规范化。

结论

此次公告虽然属于公司与关联方之间的经营管理权调整，但由于管理费用金额较小且对公司核心业务无实质性影响，事件本身对公司基本面和股东权益影响有限，预计不会成为短期内影响公司股价的重大利好或利空因素。

免责声明

本文仅为基于公司公告的新闻解读，不构成任何投资建议。投资者据此操作，风险自负。

In English

In-Depth Analysis of Tongfang Co., Ltd.’s Termination of Entrusted Management Agreement and Related Party Transaction Progress

Key Points Summary

Tongfang Co., Ltd. (Stock Code: 600100) has signed a Termination Agreement with its former controlling shareholder, China Baoyuan Investment Co., Ltd. (“China Baoyuan”), regarding the termination of an entrusted management agreement.
The agreement concerns the entrustment of certain shareholder rights and management authority of China Baoyuan’s wholly-owned subsidiary, China Nuclear Medical Industry Management Co., Ltd. (“China Nuclear Medical”), to Tongfang.
Under the original agreement, Tongfang would receive an annual management fee of RMB 400,000 (tax included) for a term of three years.
Due to changes in objective circumstances, both parties have agreed to terminate this arrangement and settle management fees based on the actual period managed.

Background and Details

On July 26, 2024, Tongfang and China Baoyuan signed the Entrusted Management Agreement, which allowed Tongfang to exercise certain shareholder and management rights over China Nuclear Medical, with a three-year term and an annual fee of RMB 400,000. This was publicly disclosed on July 27, 2024.

Recently, due to changes in circumstances, both parties entered into a Termination Agreement, which ends the previous arrangement from the effective date of the termination, with fees settled for the actual period managed.

Impact on the Company & Key Issues for Investors

The company states that this termination will not adversely affect its normal operations.
No significant impact is expected on the company’s future financial position or operating results.
No harm to shareholders, especially minority shareholders, is anticipated.
Given the relatively small management fee (RMB 400,000/year), the termination has a negligible impact on company performance and is unlikely to cause significant share price volatility.
The termination of this related party transaction clarifies business dealings with the former controlling shareholder and supports corporate governance transparency.

Conclusion

Although this announcement reflects an adjustment in management rights between the company and a related party, given the small financial impact and lack of material effect on core operations, the event is not expected to be a major driver of stock price movement in the short term.

Disclaimer

This article is an interpretation of the company’s announcement and does not constitute investment advice. Investors act at their own risk.